Summary Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.
Didox (M,3-4trihydroxybenzamide) , an inhibitor of ribonucleotide reductase, interferes with the synthesis of DNA by blocking the production of deoxyribonucleotides. The cellular content of the enzyme closely correlates with a cell's replicative activity and so its inhibition could be a useful approach in the treatment of malignant disease (Elford et al., 1970) . Didox has been shown to have anti-tumour effects in a variety of experimental systems including L1210 and P388 leukaemias, B16 melanoma, Lewis' lung tumour and several human tumour xenografts (Elford & Van't Reit, 1985) . It is more potent as an inhibitor of ribonucleotide reductase than hydroxyurea (Elford et al., 1979) .
A phase I study involving 34 patients with a variety of cancers established the dose-limiting toxicity of didox as disturbance of hepatic and renal function (Veale et al., 1988) . It was found that didox could be administered safely by slow intravenous injection at a dose of 6 g m-2. No responses were seen in the study, but only three patients received more than one course at 6 g m2 or more. Because of its potency in inhibiting the target enzyme and its potential use in combination (Elford et al., 1991) 2 in two. Ten patients had operable disease at presentation with a median post-operative disease-free interval of 32 months (range 10-138). Twelve had a median of 2 prior endocrine treatments (range 1-5). Previous chemotherapy regimens included anthracyclines (12 patients), the combination of cyclophosphamide, methotrexate and 5-fluorouracil (5), mitomycin C with vinblastine (1), chlorambucil (1) and mitoxantrone (1). Metastatic patterns included involvement at the following sites: skin and chest wall (12 patients), lymphatic (9), breast (4), bone (6), lungs/pleura (6), liver (2). The median time from the diagnosis of breast cancer to starting didox was 62 months (range 18-198) .
Thirty-two courses of didox were administered with a median of two for each patient (range 1-4). No patient responded to didox, all having progressive disease within 2 months of starting treatment. Twelve patients have died; median survival was 3.5 months (range 1.5-12).
Toxicity was mild. There was no significant myelotoxicity. In 32 courses of treatment, nausea/vomiting was recorded on ten occasions of severity WHO grade 1 (5), grade 2 (2) and grade 3 (3). Two patients developed grade 3 alopecia. There was no other significant toxicity.
Discussion
Ribonucleotide reductase inhibitors, notably hydroxyurea have not had wide application in the treatment of cancer.
The potency of didox as an enzyme inhibitor and its activity in experimental systems has led to its clinical testing. In this study, we have demonstrated no activity for a particular schedule against advanced breast cancer in patients who have had prior chemotherapy. For this cancer, several useful systemic treatments exist, both hormonal and cytotoxic, for the palliation of metastatic disease. The availability of standard treatments make this cancer a difficult test bed for new agents such as didox because they are usually given, as in this trial, to patients who have already been exposed to several different treatments. They are at a late stage in the clinical course of the disease and resistance to further treatments is likely.
The schedule of treatment used in this study was determined from a phase I study (Veale et al., 1988) . Possibly other schedules of didox could have greater efficacy; the relative lack of toxicity noted in this study might suggest that higher dose intensity is needed. Nevertheless, despite these mitigating comments, the disappointing results in the study do not encourage further testing of didox as a single agent in metastatic breast cancer.
The preclinical data indicating potentiation of other agents, perhaps by inhibiting rates of DNA repair, leave the possibility open for further studies using didox with certain other drugs. As with other antimetabolites, such as cytosinearabinoside, a daily schedule over several days might be more efficacious. Any future studies with didox will need to explore different schedules.
